pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial
Boehringer Ingelheim
Boehringer Ingelheim is a pharma organization headquartered in Ingelheim am Rhein, DE. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstruc
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
- Employees
- 46,699
- Programs
- 193
- Drugs
- 113
- Patents
- 25
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
Phase 1 · other · G12D/G12V Pancreatic Ductal Adenocarcinoma
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer for G12D/G12V Pancreatic Ductal Adenocarcinoma is a Phase 1 program (other) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Internal code KISIMA-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Modality
- other
- Indication
- G12D/G12V Pancreatic Ductal Adenocarcinoma
- Status
- active
- Trials
- 1